| Recruiting | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) Non-small Cell Lung Cancer (NSCLC) | Phase 3 | 2025-08-21 |
| Recruiting | A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastati Non Small Cell Lung Cancer | Phase 3 | 2024-11-27 |
| Active Not Recruiting | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | 2024-03-14 |
| Recruiting | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma | Phase 3 | 2023-06-05 |
| Completed | Study the Effect of Omeprazole on AB-106 Pharmacokinetics Pharmacokinetic Study | Phase 1 | 2022-11-02 |
| Withdrawn | Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC Advanced Breast Cancer, Metastatic Breast Cancer, Breast Cancer | Phase 1 / Phase 2 | 2022-09-01 |
| Withdrawn | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC Prostate Cancer, Prostatic Cancer, Cancer of Prostate | Phase 1 / Phase 2 | 2022-09-01 |
| Terminated | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer | Phase 1 | 2022-03-29 |
| Active Not Recruiting | Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC Non Small Cell Lung Cancer | Phase 2 | 2021-09-01 |
| Completed | A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 Solid Tumor | Phase 1 | 2021-07-19 |
| Completed | A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin Solid Tumor | Phase 1 | 2021-07-13 |
| Terminated | Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion Solid Tumor | Phase 2 | 2021-06-01 |
| Terminated | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors Glioma, Glioma, Malignant, Glioma, Mixed | Phase 1 | 2020-12-08 |
| Active Not Recruiting | A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene Non Small Cell Lung Cancer | Phase 2 | 2020-07-07 |
| Completed | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Solid Tumors | Phase 1 | 2014-09-01 |
| No Longer Available | Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms | — | — |